From First Patients to Commercial Scale: A CAR-T Therapy Playbook for Autoimmune Disease
As CAR-T therapies expand into autoimmune diseases, developers face a fundamental challenge: how to deliver personalized treatments safely, reliably, affordably and at a scale capable of supporting thousands of patients.
Join us for this real-world look at the transition from clinical manufacturing to commercial readiness. We'll discuss translational findings from patients treated with investigational rese-cel manufactured on Cellares' automated Cell Shuttle® platform, including product safety, consistency and early clinical experience. We'll also examine how automation is changing the economics and scalability of CAR-T manufacturing.
Drawing on their experiences, our experts will explore technology transfer, regulatory comparability, manufacturing reliability, capacity expansion and strategies for manufacturing thousands of patient doses annually.
You'll leave with practical insights into building a manufacturing strategy that evolves from clinical development to commercial supply. Register today!